JPRN-UMIN000026493已完成1 期
Phase I study safety and immunogenicity of vaccination with XAGE1 long peptides in patients with advanced lung adenocarcinoma - XAGE1 cancer vaccine against advanced lung adenocaricinoma
Department of Immuno-Oncology, Kawasaki Medical School0 个研究点目标入组 10 人开始时间: 2017年5月22日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Patients with HIV antibody positive. (2) Patients with HCV antibody positive. (3) Patients with HBs antigen or HBV-DNA positive. (4) Patients with active autoimmune disease. (5) History of serious anaphylaxis induced by antibody preparation. (6) Within 4 weeks after treatment with anticancer agent, immune suppressant, immune enhancer, cytokine therapy, radiotherapy or surgery for the primary disease. (7) Patients with double cancer. (8) Patients who need continuous systemic administration of adrenocorticosteroid. (9) Refuse to use birth control including condom etc. from the time of obtaining the first consent to 24 weeks after the final administration of the study drug (except female after menopause (1 year or more after the last menstruation) and female/male after the operation for sterilization). (10) Patients with active infection. (11) Patients with psychosis or dementia. (12) Patients who have received hematopoietic stem cell transplantation. (13) Any other inadequacy for this study.
研究者
相似试验
已完成
不适用
Phase I Study: safety and immunogenicity of vaccination with XAGE1B long peptides combined with poly-ICLC in patients with pulmonary adenocarcinomalung carcinomanon small cell lung cancer1003866610029107NL-OMON45223eids Universitair Medisch Centrum30
已完成
1 期
Study to evaluate safety and possible adverse reactions, especially serious, with a vaccine for measles and rubella in healthy subjects.Measles and RubellaRBR-9hckj4Bio-Manguinhos/Fiocruz/MS
招募中
不适用
A Phase I trial to assess safety and immunogenicity of i.d. DNA priming and i.m. MVA boosting in healthy volunteers in MozambiqueHIV/AIDSPACTR201106000304583Swedish Institute for Infectious Disease Control24
招募中
1 期
A phase I trial to assess safety and immunogenicity of an HLAII-targeted DNA vaccine against influenza H7N9Influenza prophylaxisCTIS2022-500706-18-01Oslo University Hospital Hf30
已完成
1 期
Safety, immunogenicity and dose finding for inactivated SARS-CoV-2 vaccine FAKHRAVAC (MIVAC)SARS-CoV-2.U07.1 COVID-19, virus identifiedU07.1 COVIIRCT20210206050259N1Organization of Defensive Innovation and Research135